Angel Biotechnology losses widen

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Angel Biotechnology, which makes stem cells for medical research, posted wider half year losses as it looks to complete the joint venture agreement with MMH.

Pre-tax loss widened to £2.86m for the six month period ended September 30th 2012 most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. Angel posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

The group, which has also suffered from client funding constraints, delays and cancellations, reported a loss per share of 0.08p compared to a loss of 0.009p previously.

Commercial Director and Acting CEO Dr Stewart White said: "The first half of 2012 has been a challenging period for Angel. The operational review of our business, measured against client requirements, has been thorough and has resulted in what we believe is the best outcome in the circumstances for our customers, staff and shareholders."

"The main outcome has been to progress the formation of the joint venture company with MMH, using our Pentlands facility, in addition to the proposed transfer of existing MMH contracts from Angel to the joint venture company."

The completion of the JV with MMH will reduce the group's cost base and will result in a lower fixed cost profile for the group and allow it to gradually scale up resources to match revenue opportunities, it explained.

"It is the aim of the board to provide a cash neutral H2 outturn at year end 2013 and to move towards positive free cash flow in 2013-14. At the same time, Angel is actively seeking strategic partnership opportunities for elements of its businesses to provide necessary contingencies and to convert market potential into earnings at an early stage," it said in a statement.

Shares in Angel Biotechnology plunged 16.47% at 0.7p at 09:00 in London.

CJ

Recommended

Too embarrassed to ask: what is short selling?
Too embarrassed to ask

Too embarrassed to ask: what is short selling?

Short sellers are often accused of unfairly driving share prices down to make a quick buck. But short selling is a perfectly legitimate – if risky – t…
26 Jan 2021
Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021